雌激素诱发大鼠原位与移植垂体催乳素瘤中催乳素基因与TGFα和TGF …

利用本实验室建立的１７β－雌二醇诱致Ｓｐｒａｇｕｅ－Ｄａｗｌｅｙ（ＳＤ）大鼠原位垂体和异体移植于肾囊的垂体同时形成催乳素瘤的动物模型,采用Ｎｏｒｔｈｅｍ印迹杂交方法,我们观察了Ｅ２长期作用（１２０ｄ）后诱发的原位与移植垂体ＰＲＬ瘤中ＰＲＬ基因和两种转化生长因子ＴＧＦα和ＴＧＦβ１基因表达水平的改变。结果表明：在Ｅ２长期作用后,原位垂体与异体移植于肾囊,从而远离下丘脑的垂体均可形成垂体ＰＲＬ瘤;原位     

雌激素诱发大鼠原位与移植垂体催乳素瘤中催乳素基因与TGFα和TGFβ1基因的表达

利用本实验室建立的17β雌二醇(17βestradiol,E2)诱致SpragueDawley(SD)大鼠原位垂体和异体移植于肾囊的垂体同时形成催乳素(prolactin,PRL)瘤的动物模型,采用Northern印迹杂交方法,我们观察了E2长期作用(120d)后诱发的原位与移植垂体PRL瘤中PRL基因和两种转化生长因子(transforminggrowthfactor,TGF)TGFα和TGFβ1基因表达水平的改变。结果表明:在E2长期作用后,原位垂体与异体移植于肾囊,从而远离下丘脑的垂体均可形成垂体PRL瘤;原位与移植垂体PRL瘤中均表现PRL基因的高表达,但移植瘤中的PRL基因表达水平低于原位垂体瘤;此外,仅在原位垂体PRL瘤中发现上述两种转化生长因子呈较高水平的表达,移植垂体PRL瘤与正常垂体中均检测不到这两种转化生长因子的表达。上述结果提示,TGFα和TGFβ1可能涉及E2诱发的原位垂体PRL瘤形成;E2诱发原位与移植垂体形成PRL瘤的机制可能不尽相同     

GRP和VIP对E2诱致的垂体催乳素（PRL）瘤细胞PRL基因转录的影响

实验应用雄性ＳＤ大鼠,皮下埋植内置１０ｍｇ雌二醇硅胶管３个月致体催乳素瘤后,取ＰＲＬ瘤细胞进行外原代培养,并应用原位杂交方法,研究不同剂量的胃泌素释放肽（ｇａｓｔｒｉｎ－ｒｅｌｅａｉｎｇｐｅｐｔｉｄｅ,ＧＲＰ）和血活性肠肽（ｖａｓｏａｃｔｉｖｅｉｎｔｅｓｔｉｎａｌｐｏｌｙｐｅｐｔｉｄｅ,ＶＩＰ）以及Ｅ２对 离体培养的垂体ＰＲＬ瘤细胞ＰＲＬ基因转录的,下,ＧＲＰ,ＶＩＰ分别与ＰＲＬ瘤细胞孵育２４ｈ后     

17－β－雌二醇诱发SD大鼠催乳素瘤形成过程中催乳素基因的表达

给ＳＤ大鼠皮下埋植内含１７－β－雌二醇硅橡胶管３０、６０、１２０天后，发现大鼠垂体重量随给药时间延长呈持续性增加；用放射免疫法测定血浆催乳素（ｐｒｏｌａｃｔｉｎ，ＰＲＬ）含量，亦明显依次升高；用Ｎｏｒｔｈｅｒｎ印迹杂交方法检测垂体细胞中ＰＲＬ基因，发现ＰＲＬｍＲＮＡ含量也依次有显著增加，但其增加却远低于血浆ＰＲＬ含量的增加，提示１７－β－雌二醇除了促进ＰＲＬ基因的转录外，还可能增加ＰＲＬｍＲＮＡ的翻译效率。     

白细胞介素2对大鼠垂体前叶细胞雌激素受体蛋白含量和基因表达的影响

采用原代无血清细胞培养技术结合免疫组织（细胞）化学和半定量反转录－ＰＣＲ方法,观察白细胞介素２（ＩＬ－２）对大鼠垂体前叶雌激素受体（ＥＲ）蛋白含量和基因表达的影响,以探讨ＩＬ－２和ＥＲ在大鼠重体前叶的相互关系。结果显示：在大鼠垂体前叶细胞有ＩＬ－２受体表达。在无血清培养条件下,ＩＬ－２能增加ＥＲα蛋白含量,促进ＥＲα基因表达,而对ＥＲβ的作用正好相反,ｒｈＩＬ－２（１０μｇ／Ｌ）作用４８ｈ后,ＥＲ     

高原适应过程中大鼠脑内β－内啡肽含量变化的研究

选用成年雄性Ｗｉｓｔａｒ大鼠,由平原（海拔５ｍ,上海）直接运送到高原（２２６１ｍ,西宁和３４６０ｍ,天峻）。以放射免疫分折法研究了大鼠在高原２４ｈ．急性缺氧期和３０ｄ慢性缺氧期中枢脑内β－内啡肽样免疫活性物质（β－ＥＰ）的含量变化。结果表明：１．大鼠在两个不同海拔（２２６１ｍ,３４６０ｍ）环境２４ｈ急性缺氧期与平原对照组相比,脑垂体内β－ＥＰ含量降低非常显著（Ｐ＜０．０１）,纹状体、丘脑、下丘脑、桥－延脑、海马内β－ＥＰ含量均增加非常显著（Ｐ＜０．０１）。２．大鼠在３４６０ｍ高原３０ｄ慢性习服期,垂体及各脑区内β－ＥＰ的含量变化呈时相性：即１—３ｄ均呈进行性增加（Ｐ＜０．０１）：３－１５ｄ呈持续性减少,除中脑、纹状体、丘脑外,均为Ｐ＜０．０１。１５－３０ｄ垂体、丘脑、皮层、纹状体内β－ＥＰ含量仍持续减少（毒体、皮层Ｐ＜０．０１）,桥－延脑、下丘脑、海马趋于回升（Ｐ＜０．０１）,中脑亦趋于回升（Ｐ＞０．０５）。脑内β－ＥＰ的这种变化可能具有十分重要的生物学意义。     

促乳素抑制培养的大鼠颗粒细胞中卵泡素介导的组织纤溶酶原激活因子的表达

本文主要是观察促乳素（ＰＲＬ）是否曩体外培养的大鼠颗粒细胞中,组织纤溶酶原激活因子（ｔＰＡ）和Ｉ型纤溶酶原激活因子抑制因子（ＰＡＩ－Ｉ）基因表达间的协调作用。我们采用了多种方法,例如ＳＤＳ－ＰＡＧＥ、免疫印迹等,来检测ＰＲＬ对ｔＰＡ和ＰＡＩ－Ｉ基因表达的作用。结果证实：（１）在离体条件下促乳素（ＰＲＬ）能刺激颗粒细胞（ＧＣ）中ＰＡＩ－Ｉ ｍＲＮＡ的合成,而ＦＳＨ无此作用。但ＦＳＨ可与ＰＲＬ协同增加     

Ca~（2＋）与含β－桐酸磷脂脂质体的相互作用

通过测定含β－桐酸（β－ＥＳＡ）的双棕榈酰磷脂酰胆碱（ＤＰＰＣ）脂质体在加入Ｃａ（２＋）后浊度,粒度及内包荧光物释放的变化,研究了Ｃａ（２＋）与ＤＰＰＣ／β－ＥＳＡ脂质体的相互作用,结果表明,ＤＰＰＣ／β－ＥＳＡ脂质体是一类对外加Ｃａ（２＋）敏感的脂质体,Ｃａ（２＋）的作用首先是引起脂质体间的集聚然后使脂质体融合;此时加速脂质体内包荧光物的释放。     

杏仁中央核注射β－内啡肽对大鼠血压和心率的影响及其机制的分析

本工作采用微量注射法向大鼠杏仁中央核注射β－Ｅｎｄ，观察β－Ｅｎｄ对大鼠血压和心率的影响，并对其作用机制进行初步分析。实验结果表明：（１）β－Ｅｎｄ（１００，２５０ｐｇ／１μｌ）可引起血压降低和心率减慢，（２）纳洛酮及β－Ｅｎｄ抗血清均可拮抗β－Ｅｎｄ的效应。（３）酚妥拉明及心得安均可翻转β－Ｅｎｄ的降低血压和减慢心率的效应。结果提示：杏仁中央核注射β－Ｅｎｄ引起的心血管效应是通过阿片受体中介的，并且与肾上腺素能神经元的活动有关。     

训练与β－内啡肽对急性运动反应关系的研究

用放射免疫法测定训练和非训练大鼠运动前、运动到５０％耐力时间（Ｔ１／２）和衰竭时丘脑下部和血浆β－内啡肽（β－ＥＰ）的含量,探索了训练与β－ＥＰ对急性运动反应的关系。结果表明：训练组大鼠丘脑下部β－ＥＰ含量在运动到Ｔ１／２和衰竭时分别较安静时提高了４％和１５％;对照组大鼠在Ｔ１／２时,β－ＥＰ的变化趋势同训练组,以后随运动生理负荷的增强而迅速降低,衰竭时较Ｔ１／２时降低了２６％,较训练组降低了３２％（Ｐ＜０．０５）。训练组大鼠血浆β－ＥＰ含量随运动开始迅速上升,Ｔ１／２时较运动前增加了５．７倍（Ｐ＜０．０１）,以后上升的幅度减小;非训练组大鼠血浆β－ＥＰ也随运动开始迅速提高（Ｐ＜０．０１）,Ｔ１／２后趋于稳定,在Ｔ１／２和衰竭时分别比训练组低２２％和２６％。表明非训练组大鼠丘脑下部β－Ｅｐ对急性运动呈明显的双相变化,训练提高了大鼠丘脑下部和血浆β－ＥＰ对衰竭运动的反应。     

Pituitary prolactin-secreting tumor formation: recent developments

Prolactinoma is the most common type of primary pituitary tumors. It occurs more frequently in women than in men. Dopaminergic agonists are effective in the shrinkage of prolactin-secreting pituitary tumor and are preferred in some patients. However, pituitary radiotherapy may enable the long-term removal of prolactin-secreting tumor cells. Recent evidence suggests that prolactinoma is a heterogeneous disorder with complicated and multifactorial etiology and pathogenesis. Apparently, a thorough understanding of prolactinoma tumorigenesis would be important. To facilitate investigations on tumorigenesis of prolactinoma, animal models for prolactinomas have been developed. These models have expedited our progress in the recent years. Many researchers consider the F(344) rat to be the most sensitive strain of rats to estrogen (E(2))-induced prolactinoma formation. Nonetheless, E(2) treatment for 60 days also induces the formation of pituitary prolactin-secreting adenoma in male Sprague-Dawley (SD) rats. Evidently, the SD rat is also a good animal for prolactinoma investigations. Following E(2) implantation, prolactinomas developed in the eutopic adenohypophysis in situ and/or ectopic pituitary grafted under the renal capsule in SD rats. These observations favor the hypothesis that prolactinoma growth is the result of pathological changes in the adenohypophysis and/or hypothalamus. In the latter case, abnormal release of hypothalamic dopamine, GABA, or brain-gut peptides (such as cholecystokinin, vasoactive intestinal polypeptide, galanin, angiotensin, opioid peptide, gastrin, gastrin-releasing peptide, pancreatic polypeptide, and adrenocorticotropic hormone) results in some of the pathological changes that may lead to hyperprolactinemia and/or prolactinoma development. Dysregulation of prolactin synthesis and secretion may be the result of prolactin gene modulation. In E(2)-induced rat prolactinomas, prolactin mRNA contents and the expression of some proto-oncogenes, e.g. c-myc and c-ras, TGFalpha and TGFbeta1 mRNA were significantly changed. The above findings are consistent with results in human prolactinoma development. In addition, in rats abnormal expression of the prolactin gene was correlated with hypomethylated status of CpG sites in exons 1, 2 and 4 of the prolactin gene, as well as the increase in hypersensitive sites to DNase 1 in the encoding region of the prolactin gene. In E(2)-treated rats, a point mutation with a base substitution from cytidine (C) to adenine (A) was found at the -36-bp site of the proximal promoter of the prolactin gene in eutopic pituitary prolactinomas, but no change was observed in the same sequence of the prolactin gene in ectopic prolactinoma. The association of a base substitution with the hyperexpression of the prolactin gene in eutopic prolactinomas suggests that different mechanisms may mediate the formation of eutopic and ectopic prolactin-secreting tumors. Melatonin decreases the expression of the prolactin gene in vitro suggesting that this pineal hormone may be a potential anticarcinogen in vivo. It has also been shown that MT(2) (Mel(1b)) melatonin receptors are expressed in anterior pituitary cells. The use of melatonin as a preventive or therapeutic drug for prolactinomas should be further investigated. In summary, improved knowledge on tumorigenesis of prolactinomas, especially in the rat model, was noted. These E(2)-induced rat prolactinoma models would facilitate future investigations, and expected results shall be fruitful and exciting for the development of future drug designs for the prevention and/or treatment of prolactin-secreting pituitary tumors.     

褪黑素通过减弱催乳素基因增强子的突变抑制大鼠垂体催乳素瘤的增生

本工作旨在探讨褪黑素(melatonin,MLT)抑制17-β-雌二醇(17-β-estradiol,E2)诱发的Sprague-Dawley大鼠垂体催乳素(prolactin,PRL)瘤增生的分子机制。结果表明,每只大鼠每日定时皮下注射一定剂量的MLT(0.25、0.50mg)能显著抑制E2诱发的大鼠垂体PRL瘤的增生;偏低(0.05mg)或过高剂量(1.00、2.00mg)的MLT也抑制PRL瘤的增生,但无统计学意义。采用PCR和DNA直接测序显示,与正常垂体对照组比较,PRL瘤中PRL基因增强子出现五处突变,-1885bp位点由C突变为G,-1857~-1855由ACA替换为G,-1792~-1791插入G,-1383~-1382插入GGTGTGTG片段,-1265~-1250缺失GTGTGTGTGTGTGTGT片段。0.25mg/dMLT处理组,PRL瘤中的PRL基因增强子上述个别突变部位仍然存在(-1885由C突变为G),突变消失(-1792~-1791无插入G),大部分表现为突变减弱(-1856~-1855缺失AC,-1385~-1384缺失TG,-1250~-1253缺失GTGT)。采用荧光素酶报告基因检测PRL基因增强子活性显示,正常垂体、PRL瘤和0.25mg/dMLT处理的PRL瘤三组中,PRL基因增强子的活性分别为(13448.17±3012.74)、(161831.67±60996.01)和(10212.17±2634.71)OD单位。PRL瘤组增强子活性较正常垂体升高11倍(P<0.001),MLT处理组增强子活性较PRL瘤组降低93.69%(P<0.001)。上述三组PRL基因增强子空间结构的分析表明,PRL基因增强子DNA的曲折程度为PRL瘤组>MLT处理组>正常垂体。以上结果证实,MLT抑制大鼠垂体PRL瘤增生的重要分子机制之一可能是减弱PRL基因增强子的突变,也提示MLT可减弱PRL基因增强子的突变,从而下调PRL基因的高表达,可能与降低DNA的曲折程度有关。     

Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression

Pituitary tumor-transforming gene (PTTG) originally isolated from GH-secreting pituitary adenoma cells causes in vitro cell transformation, in vivo tumorigenesis, and induces basic fibroblast growth factor. These functions require an intact C-terminal proline-proline-serine-proline motif. PTTG1 is abundantly expressed in human pituitary tumors and plays a role in the early stages of experimental prolactinoma formation. We now determined direct effects of PTTG1 on hormonal phenotypes of functional pituitary tumor cells. Overexpression of PTTG1 C terminus (amino acids 147-202) containing intact proline-proline-serine-proline motifs in rat prolactin (PRL)- and GH-secreting GH3 cells markedly abrogates PRL mRNA expression by more than 90% (P < 0.001) and hormone levels (P < 0.001) and PRL promoter activity (P < 0.01) compared with control vector cells or to a PTTG1 C terminus mutant (P163A, S165Q, P166L, P170L, P172A, and P173L). Wild-type PTTG1 C-terminal transfectants formed smaller (P < 0.05) sc tumors in rats compared with control or mutated PTTG1 C-terminal transfectants. Estrogen (10 nm) treatment for 48 h partially restored PRL expression in stable wild-type PTTG1 C-terminal transfectants. These results indicate that targeting PTTG1-mediated signaling alters the hormonal phenotype in pituitary cells and disrupted PTTG1 action may be a potential subcellular therapeutic tool for repressing PRL hypersecretion.     

转录因子E2F-1与垂体肿瘤转化基因（PTTG）在大鼠PRL瘤中的表达

目的通过检测垂体肿瘤转化基因（PTTG）与腺病毒E2启动子结合因子1（E2F-1）在大鼠催乳素（PRL）瘤中的表达来探讨两者在PRL瘤发生发展过程中的作用。方法 40只大鼠随机分为两组：实验组（E组,n=20）：皮下植入17β-雌二醇的方法诱发大鼠PRL瘤;对照组（C组,n=20）：皮下植入空白硅胶管。雌激素诱导10周后处死大鼠,心脏穿刺取血,4%多聚甲醛体内灌流取出脑垂体,称重,ELISA方法检测两组大鼠血清PRL水平,垂体组织行病理组织学观察,免疫组化SP方法检测两组大鼠垂体组织中PTTG蛋白质、E2F-1蛋白质的表达。结果雌二醇作用10周后,据垂体重量、垂体组织学变化和血清PRL水平证实PRL瘤诱导成功。PRL瘤组中,PTTG蛋白质、E2F-1蛋白质均明显高于对照组,差异具有统计学意义（P〈0.01）;且PTTG蛋白质和E2F-1蛋白质的表达呈明显正相关（γ=0.764,P〈0.01）。结论 PTTG与E2F-1在大鼠PRL瘤中共同过度表达,参与了大鼠PRL瘤的发生发展。     

Stage-sensitive blockade of pituitary somatomammotrope development by targeted expression of a dominant negative epidermal growth factor receptor in transgenic mice

The epidermal growth factor receptor (EGFR) and its ligands EGF and transforming growth factor-alpha (TGF alpha) are expressed in the anterior pituitary, and overexpression of TGF alpha in the lactotrope cells of the pituitary gland in transgenic mice results in lactotrope hyperplasia and adenomata, suggesting a role for EGFR signaling in pituitary cell proliferation. To address the role of EGFR signaling in pituitary development in vivo, we blocked EGFR signaling in transgenic mice using the dominant negative properties of a mutant EGFR lacking an intracellular protein kinase domain (EGFR-tr). We directed EGFR-tr expression to GH- and PRL- producing cells using GH and PRL promoters, and a tetracycline-inducible gene expression system, to allow temporal control of gene expression. EGFR-tr overexpression in GH-producing cells during embryogenesis resulted in dwarf mice with pituitary hypoplasia. Both somatotrope and lactotrope development were blocked. However, when EGFR-tr overexpression was delayed to the postnatal period either by directing its expression with the PRL promoter or by delaying the onset of induction with tetracycline in the GH cells, no specific phenotype was observed. Lactotrope hyperplasia during pregnancy also occurred normally in the PRL-EGFR-tr mice. These data suggest that EGFR signaling is required for the differentiation and/or maintenance of somatomammotropes early in pituitary organogenesis but not later in life. (Molecular Endocrinology 15: 600-613, 2001)     

HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy

Dopamine agonist resistance or intolerance is encountered in approximately 20% of prolactinoma patients. Because human epidermal growth factor receptor 2 (HER2)/ErbB2 is overexpressed in prolactinomas and ErbB receptor ligands regulate prolactin (PRL) gene expression, we tested the role of HER2/ErbB2 in prolactinoma hormone regulation and adenoma cell proliferation to assess the rationale for targeting this receptor for prolactinoma therapy. As we showed prolactinoma HER2 overexpression, we generated constitutively active HER2-stable GH3 cell transfectants (HER2CA). PRL mRNA levels were induced approximately 250-fold and PRL secretion was enhanced 100-fold in HER2CA cells, which also exhibited increased proliferation. Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1. Lapatinib also suppressed colony formation in soft agar more than gefitinib. Oral lapatinib treatment caused tumor shrinkage and serum PRL suppression both in HER2CA transfectant-inoculated Wistar-Furth rats and in estrogen-induced Fischer344 rat prolactinomas. In cultured human cells derived from resected prolactinoma tissue, lapatinib suppressed both PRL mRNA expression and secretion. These results demonstrate that prolactinoma HER2 potently induces PRL and regulates experimental prolactinoma cell proliferation. Because pituitary HER2 signaling is abrogated by TKIs, this receptor could be an effective target for prolactinoma therapy.     

Identification of source of excessive ACTH production by improved selective venous sampling: simultaneous assay of PRL as a pituitary marker

To identify an obscure site of excessive ACTH production, selective venous sampling was performed by Seldinger's method in a 32-year-old man. Differential diagnosis between an ectopic ACTH producing tumor and Nelson's syndrome was quite inconclusive in this patient in spite of extensive clinical and laboratory evaluations, including pituitary surgery. In this study, PRL was measured in every sample as a reliable marker for pituitary drainage. Significantly higher rations (2.6 to 5.3) of catheter to peripheral (C/P) concentration of PRL at sites closer to the pituitary indicated successful samplings of pituitary drainage. C/P ratios of ACTH correlated very closely (correlation coefficient = 0.906, p less than 0.01) with those of PRL at every sampling site. Thus, it was concluded that the site of excessive ACTH production in this patient was in the pituitary gland. The methods applied in this study appear to be useful in differentiating ectopic from eutopic production of other pituitary hormones as well.     

Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline

We report the case of a giant prolactinoma in a 7-year-old boy, which was complicated by unilateral exophthalmos. The initial levels of prolactin (PRL) were about 80,000 microU/ml. Treatment with cabergoline (CAB) resulted in rapid normalization of serum PRL (6 weeks after initiation of treatment) and reduction of tumor size. In particular, magnetic resonance imaging (MRI), which was done 2.5 months after the patient was put on CAB, revealed tremendous improvement with a decrease in the size of the tumor which now showed no extrasellar extension. Subsequent MRI studies demonstrated further improvement. Exophthalmos, anisocoria and visual fields improved. In summary, this patient represents the first report of the therapeutic use of CAB as the primary mode of treatment in a 7-year-old boy with infiltrative giant prolactinoma complicated by unilateral exophthalmos. It is a noninvasive treatment that can preserve and restore vision, as well as pituitary function, and is preferable to surgery or radiation in the treatment of prolactin-secreting macroadenoma in childhood and adolescence.     

Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats

The process of angiogenesis has been found to be essential for the development of estrogen-induced pituitary prolactinoma in Fischer 344 rats. Thalidomide [(alpha-(N-phthalimido)-glutarimide] is known to be a potent immunomodulatory drug with antiangiogenic properties, but its effect on lactotroph cell secretory function and pituitary prolactinoma formation has not been described yet. The purpose of this study was to examine the effects of thalidomide on secretion of prolactin (PRL) and vascular endothelial growth factor (VEGF), cell proliferation, apoptosis and angiogenesis within the anterior pituitary gland in long-term diethylstilboestrol (DES)-treated male F344 rats in vivo and in vitro. It was found that DES sharply increased serum PRL and VEGF levels. On the other hand, simultaneous treatment of F344 rats with thalidomide for the last 15 days of the experiment attenuated the stimulatory effect of DES on PRL and VEGF secretion. It also diminished prolactin cell proliferation evaluated as the number of proliferating cell nuclear antigen (PCNA)-positive stained cell nuclei and increased the number of apoptotic bodies determined by the terminal deoxynucleotidyl-mediated dUTP nick-end labeling (TUNEL) method in sections of the DES-induced pituitary prolactinoma. The density of pituitary microvessels evaluated by microscopic counting of CD-31-positive blood vessels was also diminished by the tested drug. In addition, thalidomide (10(-4) to 10(-6) M) inhibited cell proliferation, prolactin and VEGF secretion from rat pituitary prolactinoma cells cultured in vitro. In conclusion, our results provide strong evidence for the antiprolactin and antitumor activity of thalidomide in experimentally DES-induced pituitary adenoma.